COLL (Collegium Pharmaceutical) Growth Rank: 5 (As of Aug. 20, 2026) — 17% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COLL Collegium Pharmaceutical Inc COLL
70 GF Score
Price $27.54
GF Value $46.82
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Collegium Pharmaceutical Growth Rank?

Collegium Pharmaceutical COLL -4.28% 70 Growth Rank is 5 as of Aug. 20, 2026, which is 17% below its 10-year median of 6.00. GuruFocus rates COLL with a GF Score™ of 70/100 and a GF Value™ of $46.82 (Possible Value Trap). The stock has 2 warning signs investors should review.

Collegium Pharmaceutical has the Growth Rank of 5.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Collegium Pharmaceutical Growth Rank Related Terms

COLL vs ETON, ALVO, PCRX: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Collegium Pharmaceutical Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's Growth Rank distribution charts can be found below:

* The bar in red indicates where Collegium Pharmaceutical's Growth Rank falls into.


COLL
70GF Score
Collegium Pharmaceutical Inc COLL
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 5 mean?
Collegium Pharmaceutical (COLL) has a Growth Rank of 5 as of Aug. 20, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Collegium Pharmaceutical and its competitors. This is 17% below median its historical median of 6.00. Over the past decade, Collegium Pharmaceutical's Growth Rank has ranged from 3.00 to 9.00.
Is Collegium Pharmaceutical's Growth Rank too high?
Collegium Pharmaceutical's current Growth Rank of 5 is 17% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. Overall, Collegium Pharmaceutical has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Collegium Pharmaceutical's Growth Rank compare to ETON and ALVO?
Collegium Pharmaceutical's Growth Rank of 5 can be compared against companies in the Drug Manufacturers industry. Historically, Collegium Pharmaceutical's own Growth Rank has ranged from 3.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Collegium Pharmaceutical and its competitors. Collegium Pharmaceutical's current Growth Rank is 5, which is 17% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Collegium Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Collegium Pharmaceutical (COLL) is currently considered Possible Value Trap. The stock's GF Value™ is $46.82, compared to a current price of $27.54 — trading 41.2% below its estimated fair value. The current Growth Rank is 5, which is 17% below median its 10-year median of 6.00. Collegium Pharmaceutical's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Collegium Pharmaceutical (COLL), the current Growth Rank is 5 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Collegium Pharmaceutical (COLL) Overvalued in 2026?

Based on GuruFocus' analysis, Collegium Pharmaceutical stock appears to be undervalued. The current stock price of $27.54 is trading 41.2% below its estimated GF Value™ of $46.82. GuruFocus considers Collegium Pharmaceutical to be Possible Value Trap.

Key valuation signals for COLL:

  • Growth Rank: 5 (17% below median its 10-year median of 6.00)
  • GF Value™: $46.82 vs. price of $27.54 (41.2% below fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the COLL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Collegium Pharmaceutical Business Description

Other Exchanges 354:Germany
Address 100 Technology Center Drive, Stoughton, MA, USA, 02072
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
70GF Score

Get the complete analysis for COLL

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.54
Price
$46.82
GF Value